The Impact of FDA's ASCA Accreditation on Medical Device Testing

Streamlining Compliance: The Impact of ASCA Accreditation on Medical Device Testing

The FDA has finalized its Accreditation Scheme for Conformity Assessment (ASCA) Program, marking a significant advancement in regulatory compliance for medical device manufacturers. With four new guidance documents, the FDA provides clear direction for both testing laboratories seeking ASCA accreditation and medtech companies navigating device testing and submission complexities. Key areas covered include Biocompatibility (aligned with the ISO 10993 series) and Basic Safety and Essential Performance (aligned with the IEC 60601/80601 series). Understanding these developments is crucial for medtech companies to strategically leverage them for compliance and market success.

Key Benefits of ASCA Accreditation for Manufacturers

Utilizing ASCA-accredited labs offers a substantial opportunity to streamline the premarket submission process, ultimately leading to faster FDA reviews, fewer deficiencies, and greater assurance that test results will be accepted. Here’s a closer look at the impacts:

  1. Streamlined Review Process: The ASCA Program is designed to bolster confidence in the testing results provided by accredited laboratories. By adhering to recognized standards, ASCA-accredited labs help ensure that the data submitted to the FDA is credible. This can lead to a reduction in additional information requests during the review process, streamlining the path to market.

  2. Enhanced Reliability in Testing: With ASCA accreditation, manufacturers can expect consistent and reliable test results in critical areas such as safety, performance, and biocompatibility. The FDA has stated they will generally accept results from these labs, especially when accompanied by an ASCA Declaration of Conformity (DoC). This reliability not only aids in compliance but also builds trust with stakeholders.

  3. Global Harmonization

    The alignment of ASCA with international standards, particularly those from the EU, allows manufacturers to prepare more effectively for global submissions. This harmonization simplifies compliance with both FDA and international regulatory frameworks, making it easier for companies to access international markets.

Implications for Medtech Companies

  1. Premarket Submission Requirements

    To take full advantage of ASCA accreditation, manufacturers must include specific documentation in their premarket submissions. This not only enhances the quality of your marketing submission, but also streamlines the FDA review process. Required documentation includes:

  • A comprehensive cover letter summarizing ASCA-related information.

  • ASCA Declaration of Conformity (DoC) 

  • Accompanying documentation (e.g. ASCA Test Reports)

2. Navigating ASCA Accredited Lab Limitations

Currently, the limited number of accredited biocompatibility labs may pose challenges, as only two are available for this type of testing. Companies need to strategically plan their testing timelines to avoid delays in submissions while monitoring the expansion of accredited labs.

In contrast, the availability of multiple accredited labs for electromagnetic compatibility (EMC) testing provides options for manufacturers. Companies should prioritize EMC testing early in their development processes to mitigate risks associated with testing bottlenecks.

    3. Long-term Compliance Strategy

Incorporating ASCA-accredited labs into the testing strategy is not just a short-term compliance measure but a long-term approach that can enhance overall product quality and market readiness. Manufacturers that align with ASCA standards will likely see improved confidence in their submissions and an expedited path to FDA approval.

Conclusion

Incorporating ASCA-accredited labs into your testing strategy is more than just a compliance measure; it offers a strategic advantage for a smoother, faster path to FDA approval. As the availability of ASCA-accredited labs increases, manufacturers should capitalize on this opportunity to enhance their testing plans. Aligning with ASCA standards will bolster confidence in the testing process and improve chances for successful market entry. This accreditation program marks a pivotal moment for the medtech industry, enabling manufacturers to streamline compliance, enhance their competitive edge, and ensure reliable testing and efficient submissions for successful product launches.

Previous
Previous

Conquer Ghana's Medical Device Market: Leveraging the USFDA for Faster Approvals

Next
Next

FDA Expands PCCP Guidance for AI Medical Devices